Compare DHX & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | ENTX |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.3M | 147.4M |
| IPO Year | 2007 | 2015 |
| Metric | DHX | ENTX |
|---|---|---|
| Price | $4.21 | $3.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.25 | ★ $9.00 |
| AVG Volume (30 Days) | 203.3K | ★ 3.6M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.10 | ★ 0.22 |
| Revenue | ★ $127,826,000.00 | $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $42.20 | ★ $14.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.44 | $0.91 |
| 52 Week High | $4.50 | $4.20 |
| Indicator | DHX | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 67.32 |
| Support Level | $3.39 | $1.48 |
| Resistance Level | $4.18 | $4.20 |
| Average True Range (ATR) | 0.34 | 0.25 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 70.72 | 91.04 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.